Abivax
Signal active
Organization
Contact Information
Overview
Abivax is a clinical-stage biotechnology company, that mobilizes the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Their aim is to use Abivax's drug development platforms to provide novel and effective treatments to patients with large unmet needs in these therapeutic areas.
About
Industries
Biotechnology, Health Care, Therapeutics
Founded
2013
Employees
101-250
Headquarters locations
Europe
Social
N/A
Profile Resume
Abivax headquartered in Europe, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $29.2B in funding across 72 round(s). With a team of 101-250 employees, Abivax is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Debt - Abivax, raised $163.5M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
6
Investors
3
Lead Investors
0
Total Funding Amount
$404.9M
Details
0
Abivax has raised a total of $404.9M in funding over 0 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|
Investors
Abivax is funded by 27 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Great Point Partners | - | FUNDING ROUND - Great Point Partners | 137.9M |
| Heights Capital Management | - | FUNDING ROUND - Heights Capital Management | 163.5M |
| Abivax | - | FUNDING ROUND - Abivax | 163.5M |
| Kreos Capital | - | FUNDING ROUND - Kreos Capital | 163.5M |
Recent Activity
There is no recent news or activity for this profile.